NEW YORK (GenomeWeb News) – Detroit R&D has landed an $800,000 grant to continue developing its technology for screening a biomarker for prostate cancer, the company said today.
Under the two-year Phase II Small Business Innovation Research award, Detroit R&D will pursue research into ELISA and microarray kits to screen non-steroidal inflammatory drug-activated gene, or NAG-1, also known as macrophage inhibitory cytokine-1 or prostate-derived factor-15.
The microarray kits will measure levels of mature NAG-1 or H6D polymorphism in serum for early detection of prostate cancer. The kit also will be developed to stage and monitor prostate cancer and treatment.
The company received $1.2 million in SBIR funding in 2003 to develop microarray-based drug screening tools and to support research into biomarkers for fetal alcohol syndrome.